Cartesian Therapeutics (RNAC) Financials

$7.39 +0.46 (+6.64%)

Closing price 04:00 PM Eastern

Extended Trading

$7.33 -0.06 (-0.87%)

As of 04:31 PM Eastern

Annual Income Statements for Cartesian Therapeutics

This table shows Cartesian Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	35	-220	-77
Consolidated Net Income / (Loss)	35	-220	-77
Net Income / (Loss) Continuing Operations	36	-220	-77
Total Pre-Tax Income	35	-239	-77
Total Operating Income	15	-86	-44
Total Gross Profit	111	26	39
Total Revenue	111	26	39
Operating Revenue	111	26	39
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	96	112	83
Selling, General & Admin Expense	24	40	30
Research & Development Expense	72	71	45
Impairment Charge	-	0.71	7.58
Total Other Income / (Expense), net	20	-152	-33
Interest Expense	3.03	2.83	0.00
Interest & Investment Income	2.07	4.96	7.39
Other Income / (Expense), net	21	-154	-41
Income Tax Expense	-0.61	-19	0.29
Basic Earnings per Share	$0.24	($49.76)	($4.48)
Weighted Average Basic Shares Outstanding	144.76M	5.17M	17.28M
Diluted Earnings per Share	$0.10	($49.76)	($4.49)
Weighted Average Diluted Shares Outstanding	145.87M	5.17M	17.36M
Weighted Average Basic & Diluted Shares Outstanding	153.32M	161.95M	25.91M

This table shows Cartesian Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-7.89	5.89	-22	-11	-9.00	-178	-57	9.63	-24	-6.05
Consolidated Net Income / (Loss)	-7.89	5.89	-22	-11	-9.00	-178	-57	14	-24	-10
Net Income / (Loss) Continuing Operations	-7.89	1.58	-18	-18	-13	-172	-57	15	-24	-12
Total Pre-Tax Income	-8.21	1.11	-18	-18	-13	-190	-57	15	-24	-10
Total Operating Income	-1.60	-8.50	-18	-19	-13	-36	-13	14	-18	-27
Total Gross Profit	21	17	5.94	5.25	6.55	8.27	5.84	33	0.39	-0.76
Total Revenue	21	17	5.94	5.25	6.55	8.27	5.84	33	0.39	-0.76
Operating Revenue	21	17	5.94	5.25	6.55	8.27	5.84	33	0.39	-0.76
Total Operating Expenses	22	25	24	24	20	45	19	20	18	26
Selling, General & Admin Expense	5.77	6.32	5.70	6.11	6.61	22	9.45	7.03	6.56	7.09
Research & Development Expense	17	19	19	18	13	22	9.74	13	11	11
Total Other Income / (Expense), net	-6.62	9.28	0.54	0.67	0.02	-154	-44	1.20	-6.86	16
Interest & Investment Income	0.71	1.14	1.33	1.39	1.30	0.94	1.16	1.20	2.57	2.45
Basic Earnings per Share	($0.05)	$0.04	($4.24)	($2.23)	($1.74)	($34.36)	($10.50)	$0.58	($1.13)	($0.35)
Weighted Average Basic Shares Outstanding	152.85M	144.76M	5.11M	5.11M	5.16M	5.17M	5.41M	16.72M	21.47M	17.28M
Diluted Earnings per Share	($0.05)	$0.04	($4.24)	($2.23)	($1.74)	($34.36)	($10.50)	$0.54	($1.13)	($0.35)
Weighted Average Diluted Shares Outstanding	152.85M	145.87M	5.11M	5.11M	5.16M	5.17M	5.41M	17.79M	21.47M	17.36M
Basic & Diluted Earnings per Share	-	$0.04	-	-	-	($34.36)	-	-	-	($0.35)
Weighted Average Basic & Diluted Shares Outstanding	153.03M	153.32M	153.43M	153.43M	155.20M	161.95M	17.80M	21.38M	25.41M	25.91M

This table details how cash moves in and out of Cartesian Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-7.40	-30	136
Net Cash From Operating Activities	-32	-51	-24
Net Cash From Continuing Operating Activities	-32	-51	-24
Net Income / (Loss) Continuing Operations	35	-220	-77
Consolidated Net Income / (Loss)	35	-220	-77
Depreciation Expense	1.29	0.84	1.15
Amortization Expense	-0.38	-0.08	0.00
Non-Cash Adjustments To Reconcile Net Income	-11	182	61
Changes in Operating Assets and Liabilities, net	-57	-14	-8.49
Net Cash From Investing Activities	-15	35	-8.74
Net Cash From Continuing Investing Activities	-15	35	-8.74
Purchase of Property, Plant & Equipment	-1.20	-0.21	-9.09
Acquisitions	0.00	6.56	0.00
Sale of Property, Plant & Equipment	-	0.00	0.35
Sale and/or Maturity of Investments	20	28	0.00
Net Cash From Financing Activities	39	-13	168
Net Cash From Continuing Financing Activities	39	-13	168
Repayment of Debt	-0.11	-27	0.00
Repurchase of Common Equity	-	0.00	-0.07
Issuance of Preferred Equity	0.00	20	40
Issuance of Common Equity	39	0.23	124
Other Financing Activities, net	0.16	-6.17	4.06
Effect of Exchange Rate Changes	0.02	-0.05	-0.02
Cash Interest Paid	2.25	1.85	0.00

This table details how cash moves in and out of Cartesian Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-25	-6.41	19	-13	-34	-2.69	27	-16	132	-6.59
Net Cash From Operating Activities	4.35	-12	-8.77	-9.90	-9.22	-23	-16	-14	14	-7.00
Net Cash From Continuing Operating Activities	4.35	-12	-8.77	-9.90	-9.22	-23	-16	-14	14	-7.00
Net Income / (Loss) Continuing Operations	-7.89	5.89	-22	-11	-9.00	-178	-57	14	-24	-10
Consolidated Net Income / (Loss)	-7.89	5.89	-22	-11	-9.00	-178	-57	14	-24	-10
Depreciation Expense	0.35	0.24	0.21	0.18	0.19	0.27	0.18	0.20	0.29	0.49
Non-Cash Adjustments To Reconcile Net Income	9.34	-13	8.49	-1.21	-1.19	176	48	2.50	14	-3.39
Changes in Operating Assets and Liabilities, net	2.35	-3.88	4.28	2.53	0.79	-22	-6.98	-31	23	6.15
Net Cash From Investing Activities	-30	5.49	28	-0.01	-	6.50	-0.60	-1.59	-6.20	-0.35
Net Cash From Continuing Investing Activities	-30	5.63	28	-0.01	-	6.50	-0.60	-1.59	-6.20	-0.35
Purchase of Property, Plant & Equipment	-0.58	-0.07	-0.13	-0.01	-	-0.06	-0.60	-1.59	-6.20	-0.71
Net Cash From Financing Activities	0.61	-	0.15	-2.59	-25	14	43	0.12	124	0.78
Net Cash From Continuing Financing Activities	0.61	-	0.15	-2.59	-25	14	43	0.12	124	0.78
Other Financing Activities, net	0.14	-	0.00	-	-	-6.17	3.03	0.12	0.06	0.85
Effect of Exchange Rate Changes	-	-	-0.02	-0.03	-0.02	0.02	-0.01	0.01	-0.02	-0.02

This table presents Cartesian Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	166	305	435
Total Current Assets	148	91	217
Cash & Equivalents	106	77	213
Accounts Receivable	9.76	5.87	0.87
Prepaid Expenses	3.78	4.97	3.14
Other Current Assets	-	2.98	0.00
Plant, Property, & Equipment, net	2.79	2.11	9.91
Total Noncurrent Assets	15	212	208
Long-Term Investments	2.00	2.00	2.00
Goodwill	0.00	48	48
Intangible Assets	0.00	151	151
Other Noncurrent Operating Assets	12	10	6.05
Other Noncurrent Nonoperating Assets	1.31	1.38	1.67
Total Liabilities & Shareholders' Equity	166	305	435
Total Liabilities	72	445	442
Total Current Liabilities	25	68	23
Accounts Payable	0.32	3.15	0.29
Accrued Expenses	14	16	12
Current Deferred Revenue	0.59	2.31	0.00
Other Current Liabilities	1.61	47	11
Total Noncurrent Liabilities	47	380	419
Noncurrent Deferred Revenue	0.00	3.54	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	0.00	16	16
Other Noncurrent Operating Liabilities	29	361	403
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	0.00	297	0.00
Total Equity & Noncontrolling Interests	94	-440	-6.80
Total Preferred & Common Equity	94	-440	-6.80
Preferred Stock	0.00	0.00	0.00
Total Common Equity	94	-440	-6.80
Common Stock	493	179	690
Retained Earnings	-395	-615	-692
Accumulated Other Comprehensive Income / (Loss)	-4.56	-4.60	-4.62

This table presents Cartesian Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	178	156	140	106	325	348	455
Total Current Assets	160	138	123	90	111	125	229
Cash & Equivalents	113	126	112	80	103	87	219
Accounts Receivable	6.93	6.84	5.39	4.90	2.01	32	4.83
Prepaid Expenses	6.31	3.79	4.26	3.49	3.32	2.04	4.13
Other Current Assets	-	1.84	1.06	1.88	2.37	3.47	0.98
Plant, Property, & Equipment, net	2.90	2.77	2.59	2.42	2.40	6.67	10
Total Noncurrent Assets	16	15	14	14	212	216	216
Long-Term Investments	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Goodwill	-	-	-	-	48	48	48
Intangible Assets	-	-	-	-	151	151	151
Other Noncurrent Operating Assets	12	11	11	10	9.56	14	14
Other Noncurrent Nonoperating Assets	1.60	1.31	1.38	1.38	1.38	1.67	1.67
Total Liabilities & Shareholders' Equity	178	156	140	106	325	348	455
Total Liabilities	93	81	74	46	442	449	455
Total Current Liabilities	24	27	29	20	37	26	21
Accounts Payable	0.21	1.06	0.27	0.38	2.52	2.86	0.52
Accrued Expenses	12	9.35	13	14	9.52	11	9.45
Current Deferred Revenue	3.82	4.23	4.23	4.14	0.41	0.00	0.00
Other Current Liabilities	1.55	1.67	1.73	1.79	24	12	11
Total Noncurrent Liabilities	70	55	45	26	405	423	433
Noncurrent Deferred Revenue	5.44	5.52	4.86	3.98	0.00	0.00	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	16	16	16
Other Noncurrent Operating Liabilities	44	33	26	22	390	407	417
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	85	75	65	60	-117	-101	0.75
Total Preferred & Common Equity	85	75	65	60	-117	-101	0.75
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	85	75	65	60	-117	-101	0.75
Common Stock	490	496	498	502	559	561	687
Retained Earnings	-401	-417	-428	-437	-671	-658	-682
Accumulated Other Comprehensive Income / (Loss)	-4.53	-4.57	-4.60	-4.62	-4.61	-4.59	-4.61

This table displays calculated financial ratios and metrics derived from Cartesian Therapeutics' official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	30.21%	-76.53%	49.64%
EBITDA Growth	905.46%	-761.19%	65.27%
EBIT Growth	610.35%	-780.38%	64.91%
NOPAT Growth	559.70%	-508.93%	49.20%
Net Income Growth	237.73%	-721.02%	64.76%
EPS Growth	145.45%	-721.02%	90.98%
Operating Cash Flow Growth	47.62%	-61.74%	53.73%
Free Cash Flow Firm Growth	4.80%	386.81%	-121.52%
Invested Capital Growth	78.60%	-1,154.68%	0.24%
Revenue Q/Q Growth	-10.61%	-24.70%	-18.83%
EBITDA Q/Q Growth	-0.21%	-379.77%	-58.62%
EBIT Q/Q Growth	-1.92%	-385.61%	-57.99%
NOPAT Q/Q Growth	-45.44%	-47.52%	17.95%
Net Income Q/Q Growth	-15.21%	-507.62%	68.38%
EPS Q/Q Growth	-62.96%	-507.62%	61.29%
Operating Cash Flow Q/Q Growth	38.27%	-28.79%	40.75%
Free Cash Flow Firm Q/Q Growth	26.78%	353.17%	-119.30%
Invested Capital Q/Q Growth	54.35%	-887.25%	-0.43%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	32.78%	-923.23%	-214.25%
Operating Margin	13.12%	-332.32%	-112.81%
EBIT Margin	31.95%	-926.17%	-217.21%
Profit (Net Income) Margin	31.94%	-844.91%	-198.97%
Tax Burden Percent	101.75%	92.04%	100.37%
Interest Burden Percent	98.23%	99.12%	91.26%
Effective Tax Rate	-1.75%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	60.82%	887.63%	103.14%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	21.73%	-102.28%	-22.84%
Return on Assets (ROA)	21.72%	-93.31%	-20.92%
Return on Common Equity (ROCE)	60.82%	6,210.18%	307.07%
Return on Equity Simple (ROE_SIMPLE)	37.71%	49.91%	1,138.25%
Net Operating Profit after Tax (NOPAT)	15	-60	-31
NOPAT Margin	13.35%	-232.62%	-78.97%
Net Nonoperating Expense Percent (NNEP)	18.93%	-165.91%	-31.49%
Return On Investment Capital (ROIC_SIMPLE)	-	13.74%	451.75%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	21.54%	155.55%	77.42%
R&D to Revenue	65.34%	274.03%	115.91%
Operating Expenses to Revenue	86.88%	432.32%	212.81%
Earnings before Interest and Taxes (EBIT)	35	-241	-85
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	36	-240	-83
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.84	0.00	0.00
Price to Tangible Book Value (P/TBV)	1.84	0.00	0.00
Price to Revenue (P/Rev)	1.56	4.11	11.70
Price to Earnings (P/E)	4.89	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	20.46%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.57	12.50	6.18
Enterprise Value to EBITDA (EV/EBITDA)	1.72	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	1.77	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	4.23	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	2.24	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.28	0.00	0.00
Long-Term Debt to Equity	0.19	0.00	0.00
Financial Leverage	-1.87	3.88	1.98
Leverage Ratio	2.80	-9.51	-4.93
Compound Leverage Factor	2.75	-9.43	-4.50
Debt to Total Capital	21.87%	0.00%	0.00%
Short-Term Debt to Total Capital	7.06%	0.00%	0.00%
Long-Term Debt to Total Capital	14.81%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	-207.11%	0.00%
Common Equity to Total Capital	78.13%	307.11%	100.00%
Debt to EBITDA	0.72	0.00	0.00
Net Debt to EBITDA	-3.04	0.00	0.00
Long-Term Debt to EBITDA	0.49	0.00	0.00
Debt to NOPAT	1.78	0.00	0.00
Net Debt to NOPAT	-7.46	0.00	0.00
Long-Term Debt to NOPAT	1.20	0.00	0.00
Altman Z-Score	0.37	-5.11	-1.63
Noncontrolling Interest Sharing Ratio	0.00%	-599.64%	-197.72%
Liquidity Ratios	-	-	-
Current Ratio	5.91	1.33	9.43
Quick Ratio	5.76	1.21	9.29
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-51	145	-31
Operating Cash Flow to CapEx	-2,633.72%	-24,835.44%	-270.81%
Free Cash Flow to Firm to Interest Expense	-16.72	51.29	0.00
Operating Cash Flow to Interest Expense	-10.44	-18.06	0.00
Operating Cash Flow Less CapEx to Interest Expense	-10.83	-18.13	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.68	0.11	0.11
Accounts Receivable Turnover	11.26	3.33	11.54
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	44.89	10.60	6.47
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	32.41	109.68	31.62
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	32.41	109.68	31.62
Capital & Investment Metrics	-	-	-
Invested Capital	-18	-224	-223
Invested Capital Turnover	-2.19	-0.22	-0.17
Increase / (Decrease) in Invested Capital	65	-206	0.54
Enterprise Value (EV)	63	325	241
Market Capitalization	173	107	455
Book Value per Share	$0.61	($2.84)	($0.27)
Tangible Book Value per Share	$0.61	($4.12)	($8.09)
Total Capital	120	-143	-6.80
Total Debt	26	0.00	0.00
Total Long-Term Debt	18	0.00	0.00
Net Debt	-110	-79	-215
Capital Expenditures (CapEx)	1.20	0.21	8.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-3.07	-54	-19
Debt-free Net Working Capital (DFNWC)	132	23	194
Net Working Capital (NWC)	123	23	194
Net Nonoperating Expense (NNE)	-21	159	47
Net Nonoperating Obligations (NNO)	-112	-80	-216
Total Depreciation and Amortization (D&A)	0.91	0.76	1.15
Debt-free, Cash-free Net Working Capital to Revenue	-2.77%	-209.16%	-48.72%
Debt-free Net Working Capital to Revenue	118.74%	86.60%	497.65%
Net Working Capital to Revenue	111.09%	86.60%	497.65%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$7.20	($49.80)	($4.48)
Adjusted Weighted Average Basic Shares Outstanding	4.83M	5.17M	17.28M
Adjusted Diluted Earnings per Share	$3.00	($49.80)	($4.49)
Adjusted Weighted Average Diluted Shares Outstanding	4.86M	5.17M	17.36M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.11M	5.40M	25.91M
Normalized Net Operating Profit after Tax (NOPAT)	10	-60	-25
Normalized NOPAT Margin	9.19%	-230.71%	-65.33%
Pre Tax Income Margin	31.39%	-917.97%	-198.23%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	11.68	-85.01	0.00
NOPAT to Interest Expense	4.88	-21.35	0.00
EBIT Less CapEx to Interest Expense	11.28	-85.09	0.00
NOPAT Less CapEx to Interest Expense	4.48	-21.43	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.09%

This table displays calculated financial ratios and metrics derived from Cartesian Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-15.22%	-43.90%	-82.53%	-86.63%	-68.37%	-50.78%	-1.65%	537.17%	-94.09%	-109.18%
EBITDA Growth	-2,716.61%	-176.57%	-160.86%	-228.07%	-70.31%	-39,021.97%	-219.79%	175.67%	-107.47%	86.22%
EBIT Growth	-494.66%	-60.72%	-162.63%	-235.32%	-60.88%	-42,593.54%	-218.57%	173.90%	-106.66%	85.99%
NOPAT Growth	18.79%	-308.34%	-219.43%	-194.13%	-717.07%	-199.35%	27.38%	205.45%	-34.52%	26.43%
Net Income Growth	55.89%	-51.85%	-175.28%	-232.39%	-14.05%	-3,114.73%	-162.31%	221.51%	-168.64%	94.23%
EPS Growth	68.75%	-63.64%	-175.28%	-232.39%	-14.05%	-3,114.73%	-162.31%	124.22%	35.06%	98.98%
Operating Cash Flow Growth	140.51%	62.34%	26.12%	19.36%	-311.69%	-96.52%	-81.60%	-45.99%	248.57%	69.93%
Free Cash Flow Firm Growth	-2,857.73%	-61.05%	74.41%	80.38%	73.79%	343.90%	876.25%	1,158.46%	832.95%	-110.67%
Invested Capital Growth	71.15%	78.60%	28.24%	13.29%	41.98%	-1,154.68%	-692.58%	-641.71%	-880.60%	0.24%
Revenue Q/Q Growth	-47.27%	-18.90%	-64.64%	-11.60%	24.80%	26.18%	-29.35%	472.69%	-98.84%	-296.12%
EBITDA Q/Q Growth	-152.52%	93.56%	-3,644.35%	-1.12%	30.15%	-1,379.34%	70.03%	123.93%	-291.50%	1.78%
EBIT Q/Q Growth	-159.05%	105.53%	-4,189.53%	-1.38%	29.80%	-1,360.02%	69.98%	123.52%	-296.31%	1.02%
NOPAT Q/Q Growth	-108.08%	-659.05%	-51.44%	-1.40%	29.90%	-178.09%	63.26%	247.23%	-189.43%	-52.10%
Net Income Q/Q Growth	-191.77%	174.66%	-467.61%	47.44%	20.94%	-1,873.54%	68.02%	124.35%	-274.78%	57.60%
EPS Q/Q Growth	-183.33%	180.00%	-467.61%	47.44%	20.94%	-1,873.54%	68.02%	105.14%	-309.26%	69.03%
Operating Cash Flow Q/Q Growth	135.47%	-372.20%	26.03%	-12.89%	6.87%	-152.70%	31.65%	9.24%	194.77%	-151.14%
Free Cash Flow Firm Q/Q Growth	-12.31%	24.09%	67.59%	28.97%	-50.01%	806.33%	3.15%	-3.15%	3.88%	-110.29%
Invested Capital Q/Q Growth	-30.53%	54.35%	-58.28%	8.07%	12.66%	-887.25%	0.01%	13.97%	-15.47%	-0.43%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
EBITDA Margin	-36.51%	-2.90%	-307.09%	-351.29%	-196.60%	-2,304.91%	-998.51%	41.72%	-6,904.39%	0.00%
Operating Margin	-7.72%	-50.59%	-309.55%	-355.08%	-199.44%	-439.54%	-228.56%	41.13%	-4,541.34%	0.00%
EBIT Margin	-39.22%	2.67%	-309.23%	-354.64%	-199.48%	-2,308.20%	-1,001.64%	41.13%	-6,978.29%	0.00%
Profit (Net Income) Margin	-38.11%	35.09%	-364.82%	-216.94%	-137.41%	-2,149.26%	-973.01%	41.37%	-6,248.84%	0.00%
Tax Burden Percent	96.09%	529.95%	121.44%	63.36%	69.02%	93.58%	99.11%	92.54%	98.98%	99.31%
Interest Burden Percent	101.12%	247.66%	97.15%	96.55%	99.80%	99.51%	98.01%	108.69%	90.47%	38.62%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	126.10%	60.82%	-23.11%	-45.21%	-49.79%	887.63%	1,207.32%	1,275.47%	-801.65%	103.14%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-28.14%	1.82%	-169.74%	-105.43%	-48.46%	-254.91%	-107.92%	9.13%	-1,191.86%	0.00%
Return on Assets (ROA)	-27.34%	23.86%	-200.25%	-64.49%	-33.38%	-237.35%	-104.83%	9.19%	-1,067.27%	0.00%
Return on Common Equity (ROCE)	126.10%	60.82%	-23.11%	-45.21%	-49.79%	6,210.18%	1,207.32%	1,275.47%	-801.65%	307.07%
Return on Equity Simple (ROE_SIMPLE)	49.14%	0.00%	-20.20%	-53.55%	-59.94%	0.00%	218.21%	226.35%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-1.12	-8.50	-13	-13	-9.15	-25	-9.34	14	-12	-19
NOPAT Margin	-5.40%	-50.59%	-216.68%	-248.55%	-139.60%	-307.67%	-159.99%	41.13%	-3,178.94%	0.00%
Net Nonoperating Expense Percent (NNEP)	-5.63%	13.23%	-8.89%	1.57%	0.14%	-158.62%	-45.31%	0.09%	-7.77%	5.70%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	5.78%	-	-	-	275.09%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	27.86%	37.65%	95.91%	116.31%	100.96%	266.59%	161.82%	21.01%	1,695.61%	0.00%
R&D to Revenue	79.86%	112.93%	313.64%	338.77%	198.47%	264.36%	166.75%	37.86%	2,945.74%	0.00%
Operating Expenses to Revenue	107.72%	150.59%	409.55%	455.08%	299.44%	539.54%	328.56%	58.87%	4,641.34%	0.00%
Earnings before Interest and Taxes (EBIT)	-8.12	0.45	-18	-19	-13	-191	-58	14	-27	-27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-7.56	-0.49	-18	-18	-13	-191	-58	14	-27	-26
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.95	1.84	2.86	2.63	2.70	0.00	0.00	0.00	458.36	0.00
Price to Tangible Book Value (P/TBV)	2.95	1.84	2.86	2.63	2.70	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.02	1.56	2.58	3.53	4.71	4.11	4.06	8.88	7.19	11.70
Price to Earnings (P/E)	6.00	4.89	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	16.66%	20.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.03	0.57	1.35	1.68	2.35	12.50	0.00	7.24	2.58	6.18
Enterprise Value to EBITDA (EV/EBITDA)	3.52	1.72	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	3.55	1.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	4.72	4.23	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	2.24	0.00	2.96	0.76	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.31	0.28	0.35	0.37	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.24	0.19	0.22	0.21	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-3.64	-1.87	-1.52	-1.36	-1.42	3.88	4.96	5.06	-5.01	1.98
Leverage Ratio	5.22	2.80	2.31	2.11	1.96	-9.51	-11.39	-13.53	9.19	-4.93
Compound Leverage Factor	5.28	6.93	2.25	2.04	1.95	-9.47	-11.16	-14.71	8.31	-1.90
Debt to Total Capital	23.51%	21.87%	26.18%	26.85%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	5.30%	7.06%	10.11%	11.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	18.21%	14.81%	16.06%	15.41%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	-207.11%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	76.49%	78.13%	73.82%	73.15%	100.00%	307.11%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.72	0.72	-2.23	-0.54	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-3.36	-3.04	8.54	2.01	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.56	0.49	-1.37	-0.31	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.96	1.78	-2.58	-0.73	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-4.51	-7.46	9.92	2.73	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.75	1.20	-1.59	-0.42	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.08	-0.33	-1.17	-2.19	-2.92	-4.57	-2.99	-1.38	-1.18	-1.19
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-599.64%	0.00%	0.00%	0.00%	-197.72%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.73	5.91	5.22	4.18	4.51	1.33	3.03	4.78	10.70	9.43
Quick Ratio	6.46	5.76	5.00	4.00	4.24	1.21	2.88	4.57	10.47	9.29
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-97	-74	-24	-17	-26	180	186	180	187	-19
Operating Cash Flow to CapEx	749.23%	-17,953.03%	-6,742.31%	-82,458.33%	0.00%	-36,384.38%	-2,644.02%	-910.27%	220.86%	-993.19%
Free Cash Flow to Firm to Interest Expense	-121.47	-91.64	-29.66	-22.64	-20.06	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	5.43	-14.68	-10.85	-13.16	-7.24	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	4.70	-14.76	-11.01	-13.17	-7.24	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.72	0.68	0.55	0.30	0.24	0.11	0.11	0.22	0.17	0.11
Accounts Receivable Turnover	17.39	11.26	11.82	3.31	5.84	3.33	5.86	2.89	9.86	11.54
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	52.61	44.89	30.33	17.95	12.97	10.60	10.03	11.68	7.58	6.47
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	20.99	32.41	30.87	110.11	62.48	109.68	62.31	126.24	37.03	31.62
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	20.99	32.41	30.87	110.11	62.48	109.68	62.31	126.24	37.03	31.62
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-39	-18	-28	-26	-23	-224	-224	-192	-222	-223
Invested Capital Turnover	-1.42	-2.19	-2.45	-1.74	-1.12	-0.22	-0.21	-0.50	-0.39	-0.17
Increase / (Decrease) in Invested Capital	96	65	11	3.98	16	-206	-195	-166	-199	0.54
Enterprise Value (EV)	128	63	112	82	81	325	-0.15	391	123	241
Market Capitalization	250	173	213	172	163	107	105	481	345	455
Book Value per Share	$0.56	$0.61	$0.49	$0.43	$0.39	($2.84)	($0.72)	($5.70)	$0.04	($0.27)
Tangible Book Value per Share	$0.56	$0.61	$0.49	$0.43	$0.39	($4.12)	($1.95)	($16.87)	($9.26)	($8.09)
Total Capital	111	120	101	89	60	-143	-117	-101	0.75	-6.80
Total Debt	26	26	26	24	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	20	18	16	14	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-122	-110	-101	-90	-82	-79	-105	-89	-221	-215
Capital Expenditures (CapEx)	0.58	0.07	0.13	0.01	0.00	0.06	0.60	1.59	6.20	0.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-4.61	-3.07	-3.85	-8.43	-9.67	-54	-29	11	-11	-19
Debt-free Net Working Capital (DFNWC)	142	132	122	104	70	23	74	99	208	194
Net Working Capital (NWC)	136	123	112	93	70	23	74	99	208	194
Net Nonoperating Expense (NNE)	6.77	-14	8.80	-1.66	-0.14	152	47	-0.08	12	-8.46
Net Nonoperating Obligations (NNO)	-124	-112	-103	-91	-83	-80	-107	-91	-223	-216
Total Depreciation and Amortization (D&A)	0.56	-0.94	0.13	0.18	0.19	0.27	0.18	0.20	0.29	0.49
Debt-free, Cash-free Net Working Capital to Revenue	-3.72%	-2.77%	-4.65%	-17.32%	-28.01%	-209.16%	-111.80%	21.15%	-23.92%	-48.72%
Debt-free Net Working Capital to Revenue	114.45%	118.74%	147.59%	212.75%	202.50%	86.60%	287.40%	182.37%	433.33%	497.65%
Net Working Capital to Revenue	109.71%	111.09%	135.24%	191.73%	202.50%	86.60%	287.40%	182.37%	433.33%	497.65%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.50)	$1.20	($4.20)	($2.10)	($1.80)	($1,030.80)	($10.50)	$0.58	($1.13)	($0.35)
Adjusted Weighted Average Basic Shares Outstanding	5.10M	4.83M	5.11M	5.11M	5.16M	172.34K	5.41M	16.72M	21.47M	17.28M
Adjusted Diluted Earnings per Share	($1.50)	$1.20	($4.20)	($2.10)	($1.80)	($1,030.80)	($10.50)	$0.54	($1.13)	($0.35)
Adjusted Weighted Average Diluted Shares Outstanding	5.10M	4.86M	5.11M	5.11M	5.16M	172.34K	5.41M	17.79M	21.47M	17.36M
Adjusted Basic & Diluted Earnings per Share	$0.00	$1.20	$0.00	$0.00	$0.00	($1,030.80)	$0.00	$0.00	$0.00	($0.35)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.10M	5.11M	5.11M	5.11M	5.17M	5.40M	17.80M	21.38M	25.41M	25.91M
Normalized Net Operating Profit after Tax (NOPAT)	-1.12	-5.95	-13	-13	-9.15	-25	-9.34	9.63	-12	-19
Normalized NOPAT Margin	-5.40%	-35.41%	-216.68%	-248.55%	-139.60%	-307.67%	-159.99%	28.79%	-3,178.94%	0.00%
Pre Tax Income Margin	-39.66%	6.62%	-300.42%	-342.41%	-199.08%	-2,296.83%	-981.71%	44.71%	-6,313.44%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-10.13	0.56	-22.73	-24.75	-10.27	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-1.40	-10.53	-15.92	-17.35	-7.18	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-10.85	0.47	-22.89	-24.77	-10.27	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-2.12	-10.61	-16.09	-17.37	-7.18	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.09%

Financials Breakdown Chart

Key Financial Trends

The data you provided appears to be Cartesian Therapeutics, Inc. (RNAC), not Selecta Biosciences (SELB). If you intended SELB, please share SELB’s latest four years of quarterly data. Below is a quick, high‑level read based on the RNAC data you supplied (last four years of quarterly results), formatted as requested.

Issuance of common equity in Q3 2024 raised about $124.4 million, with net cash from continuing financing activities around $124.5 million, boosting liquidity.
Cash balance was strong in Q3 2024, with Cash & Equivalents of about $219.2 million, supporting near‑term liquidity.
Net change in cash and equivalents in Q3 2024 was a sizable positive swing (+$131.97 million) driven by financing activity, helping accumulate cash reserves.
Revenue has been volatile across quarters (for example, about $33.4 million in Q2 2024 vs. much smaller amounts in other periods), indicating uneven top‑line momentum.
Non‑cash adjustments to reconcile net income were large in multiple periods (e.g., a substantial amount in Q3 2024), which can distort operating cash flow signals.
Balance sheet shows a substantial asset base and an equity cushion, but retained earnings are negative in several periods, signaling ongoing losses and balance‑sheet risk.
Net income declined sharply in several quarters and was negative in recent periods (e.g., Q3 2024 net income to common shareholders about −$24.18 million; Q4 2024 about −$6.05 million), underscoring profitability challenges.
Operating cash flow has been negative in multiple quarters (for example, Q4 2024 net cash from continuing operating activities around −$7.00 million; Q1–Q2 2024 also negative in several periods), pointing to recurring cash burn from operations.
Net change in cash swung from a large positive in Q3 2024 to a negative result in Q4 2024, signaling liquidity pressure despite prior financing inflows.
Significant negative retained earnings and declines in total equity raise questions about long‑term solvency if losses persist without sustained, repeated financing or meaningful profitability improvements.

05/05/26 06:01 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Cartesian Therapeutics' Financials

When does Cartesian Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Cartesian Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cartesian Therapeutics' net income changed over the last 2 years?

Cartesian Therapeutics' net income appears to be on an upward trend, with a most recent value of -$77.42 million in 2024, falling from $35.38 million in 2022. The previous period was -$219.71 million in 2023. View Cartesian Therapeutics' forecast to see where analysts expect Cartesian Therapeutics to go next.

What is Cartesian Therapeutics' operating income?

Cartesian Therapeutics' total operating income in 2024 was -$43.90 million, based on the following breakdown:

Total Gross Profit: $38.91 million
Total Operating Expenses: $82.81 million

How has Cartesian Therapeutics' revenue changed over the last 2 years?

Over the last 2 years, Cartesian Therapeutics' total revenue changed from $110.78 million in 2022 to $38.91 million in 2024, a change of -64.9%.

How much debt does Cartesian Therapeutics have?

Cartesian Therapeutics' total liabilities were at $441.83 million at the end of 2024, a 0.6% decrease from 2023, and a 513.2% increase since 2022.

How much cash does Cartesian Therapeutics have?

In the past 2 years, Cartesian Therapeutics' cash and equivalents has ranged from $76.91 million in 2023 to $212.61 million in 2024, and is currently $212.61 million as of their latest financial filing in 2024.

How has Cartesian Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Cartesian Therapeutics' book value per share changed from 0.61 in 2022 to -0.27 in 2024, a change of -143.6%.

Related Companies

Financial statements for NASDAQ:RNAC last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cartesian Therapeutics (RNAC) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Cartesian Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cartesian Therapeutics (RNAC) Financials

Annual Income Statements for Cartesian Therapeutics

Quarterly Income Statements for Cartesian Therapeutics

Annual Cash Flow Statements for Cartesian Therapeutics

Quarterly Cash Flow Statements for Cartesian Therapeutics

Annual Balance Sheets for Cartesian Therapeutics

Quarterly Balance Sheets for Cartesian Therapeutics

Annual Metrics And Ratios for Cartesian Therapeutics

Quarterly Metrics And Ratios for Cartesian Therapeutics

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Cartesian Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools